Oblon’s Biotechnology Group includes members with specific experience in fields such as pharmaceuticals, therapeutics, formulations, diagnostics, molecular and cellular biology, immunology and autoimmunity, recombinant antigens and antibodies, virology, vaccines, biologics, gene therapy, genetic engineering, genomics and proteomics, microarray technologies, microbiology, biochemistry, molecular-genetics drug delivery, RNA interference, neurology and bioinformatics,.
The Group has assisted clients in worldwide prosecution, reexamination, due diligence, litigation, interferences, post-grant proceedings, and acquisitions. We understand what creates commercial value of a patent portfolio, and we have an appreciation of the interface between prosecution and enforcement. Due to the wide range of clients—from large multinational companies to startups—the Group has the experience of providing legal services to facilitate the wide-ranging business goals of such differing entities.
Our Alexandria, Virginia location adjacent to the U. S. Patent and Trademark Office (USPTO) enables us to regularly meet face-to-face with USPTO patent examiners, thereby enhancing our ability to obtain protection for our clients' inventions while keeping cost to a minimum. Our close working relationship with the USPTO is an important contributor to our record of success in obtaining patent protection for our clients.
Our attorneys are active in the business community and understand the financial constraints that are faced by new and established businesses. We offer various alternative fee arrangements as well as initial meetings at no charge, to learn about the client’s technology and services, history, goals and preferences and to identify communication and billing requirements. We then meet the clients to ensure that we are current with their business strategies and goals, which enables us to meet the client’s needs and expectations. Our collective experience helps clients capitalize on opportunities while minimizing risk. We recognize the large financial demands on research, development and FDA approval, and we are committed to providing effective and efficient solutions at a reasonable cost. We have the resources and experience to formulate and execute global patent protection strategies for our clients, regularly appearing on their behalf in the USPTO, before the International Trade Commission (ITC) and in courts throughout the United States.
As with all of Oblon’s practice groups, we assemble the best team for each client or matter, combining the skills and experience in the science and the law. In addition, we have foreign-language abilities in, for example, German, French, Chinese, Japanese, Korean and Russian, which can facilitate communications with our clients.